Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 mars 2025 08h00 HE | Source: Liquidia Corporation

Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference

Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in 6MWD, cardiac effort and QoL.
07 janv. 2019 07h00 HE | Source: Liquidia Technologies, Inc.

Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial

LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDANDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2019 ...
31 oct. 2018 07h00 HE | Source: Liquidia Technologies, Inc.

Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen Bloch appointed as...